Home
Lyra Therapeutics

Lyra Therapeutics Market Share Analysis for December 2025

Our Offices Lyra Therapeutics, Inc. 480 Arsenal Way Watertown, MA 02472 617.393.4600 contactus@lyratx.com

Health > Biotechnology and Pharmaceuticals

Domainlyratherapeutics.com

Year Founded2011

Employees51 - 200

Annual Revenue< $1M

Lyra Therapeutics

Lyra Therapeutics (including company regionals)

lyratherapeutics.com

See more website traffic and engagement information

Lyra Therapeutics Revenue up to December 2025 is < 1M

revenue generated by Lyra Therapeutics top domains

Lyra Therapeutics top domains revenue over 3 years

Revenue for Lyra Therapeutics top domains

lyratherapeutics.com< 1M

See more with Sales Intelligence

Total visits to Lyra Therapeutics's top domains

Understand Lyra Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

lyratherapeutics.com4.3K

See more with Sales Intelligence

Avg. visit duration in Lyra Therapeutics's top domains

Analyze Lyra Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

lyratherapeutics.com00:00:27

See more with Sales Intelligence

Avg. pageviews on Lyra Therapeutics's top domains

See how Lyra Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

lyratherapeutics.com1.88

See more with Sales Intelligence

Lyra Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Lyra Therapeutics

These are the website technologies, by industry, used by Lyra Therapeutics top domains

Widget (5)

Twemoji

Audio Video Media (1)

Vimeo

Content Management System (1)

WordPress

Conversion & Analytics (1)

Google Analytics

More Technologies

4

See all

News & Signals from Lyra Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsLyra Therapeutics Inc. launched Phase 3 ENLIGHTEN 1 trial of LYR-210 for chronic rhinosinusitis on May 6th '24.WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotech company, announced today that its Phase 3 ENLIGHTEN 1 trial of LYR-210 for chronic rhinosinusitis (CRS) failed to meet its primary endpoint.

NewsLyra Therapeutics Inc. receives award Innovation / R&D category.Lyra Therapeutics, Inc. (LYRA) has disclosed a new risk, in the Innovation / R&D category.

NewsLyra Therapeutics Inc. is developing LYR-210 and LYR-220.Lyra Therapeutics is developing LYR-210 and LYR-220, its two product candidates in late-stage development for the treatment of CRS.